ReferenceID 5613
Menthone supplementation protects from allergic inflammation in the lungs of asthmatic mice
Eur J Pharmacol
To screen potent terpenoid compounds against allergic inflammation in vitro and in vivo, five terpenoid compounds including menthone, farnesol, oridonin, β-escin and lupeol, were first selected to compare their anti-alle
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 5613
- Evidence Id
- 22203
- Core Evidence Id
- 22203
- Source Reference Id
- 4448
- Herb2 Reference Id
- HBREF005245
- Subject Paper Key
- HBIN033440_35988786
- Pubmed Id
- 35988786
- Doi
- 10.1016/j.ejphar.2022.175222
- Paper Title
- Menthone supplementation protects from allergic inflammation in the lungs of asthmatic mice
- Paper Abstract
- To screen potent terpenoid compounds against allergic inflammation in vitro and in vivo, five terpenoid compounds including menthone, farnesol, oridonin, β-escin and lupeol, were first selected to compare their anti-allergic inflammation potential using mouse lung mast cells in vitro. Among five selected terpenoid compounds, just menthone treatment decreased TNF-α/IL-10 secretion ratios in lipopolysaccharide -stimulated mast cells in vitro. As a result, menthone was further chosen to treat ovalbumin (OVA)-sensitized and challenged BALB/c mice by gavage for 5 weeks. There were six groups including dietary control (DC group, 0 mg menthone/kg b.w./day), 8 (ML group), 40 (MM group) as well as 200 mg menthone/kg b.w./day (MH group) by gavage, positive control (PC group, 3 mg dexamethasone/kg b.w. by gavage before OVA challenge) and non-treatment control (NTC group, normal mice without treatment) in the experiment. Changes of inflammatory mediators, cell distribution, Th1/Th2 and pro-/anti-inflammatory cytokines secretion as well as relative gene expression amounts of six receptors related to allergic inflammation in the lungs and airways were measured. The results showed that middle menthone supplementation (40 mg menthone/kg b.w./day) in vivo decreased protein and eotaxin, but increased Th1 cytokine levels in the bronchoalveolar lavage fluid. Menthone supplementation inhibited eosinophilia, mast cell degranulation, chemokine (C-C motif) receptor 3 (CC receptor 3) and chemokine (C-X-C motif) receptor 1 (CXC receptor 1) gene expression amounts in the lungs, but restored the percentage of monocytes/macrophages. Our results suggest that menthone supplementation may alleviate allergic asthma through regulating airway allergic inflammation, protein overproduction, eosinophils infiltration, Th1/Th2 immune balance, CC receptor 3 and CXC receptor 1 gene expression amounts in the lungs but restoring the percentage of monocytes/macrophages in allergic asthmatic mice.
- Journal
- Eur J Pharmacol
- Publish Year
- 2022
- Experiment Subject
- mouse; lipopolysaccharide -stimulated mast cells
- Experiment Type
- Animal Experiment
- Phenotype Related
- Airway Allergic Inflammation; Allergic Asthma; Allergic Inflammation
- Paper Title Cn
- Paper Title En
- Menthone supplementation protects from allergic inflammation in the lungs of asthmatic mice
- Bilingual Status
- semi_complete